HUMAN MONOCLONAL ANTIBODIES TO TNF: NEW OPPORTUNITIES IN TREATMENT OF JUVENILE IDIOPATHIC SPONDYLITIS

Abstract

This article contains an example of a successful clinical use of human monoclonal antibodies to tumor necrosis factor (TNF) — adalimumab in patients with severe juvenile idiopathic spondylitis, characterized by resistance to standard antirheumatic treatment and secondary resistance to recombinant (chimeric) antibodies to TNF. Adalimumab treatment in a short time has helped to overcome secondary ineffectiveness of infliximab treatment, to rapidly decrease the activity of the disease, to reach functional improvement of peripheric joints, to improve patient’s quality of life. The aforesaid medication has stopped steady progression of further incapacitation of the patient and has evoked clinical remission of the disease.Key words: children, juvenile idiopathic spondylitis, adalimumab, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (3): 150–156)